Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Min Yuen Teo

Showing results (21-30 of 45) with videos related to

Pageof 5
Sort By:
Journal of the National Comprehensive Cancer Network : JNCCN|December 7, 2020
Prevalence of Insomnia in an Oncology Patient Population: An Irish Tertiary Referral Center ExperienceEmily C Harrold, Ahmad F Idris, Niamh M Keegan, et al.
European Urology|August 6, 2020
Fibroblast Growth Factor Receptor 3 Alteration Status is Associated with Differential Sensitivity to Platinum-based Chemotherapy in Locally Advanced and Metastatic Urothelial CarcinomaMin Yuen Teo, Jose Mauricio Mota, Karissa A Whiting, et al.
Cancers|June 10, 2023
Results from a Phase 1b/2 Study of Ibrutinib Combination Therapy in Advanced Urothelial CarcinomaNataliya Mar, Yousef Zakharia, Alejandro Falcon, et al.
British Journal of Cancer|January 21, 2021
Natural history, response to systemic therapy, and genomic landscape of plasmacytoid urothelial carcinomaMin Yuen Teo, Hikmat Al-Ahmadie, Kenneth Seier, et al.
The American Journal of Surgical Pathology|May 29, 2019
PD-L1 Expression in Urothelial Carcinoma With Predominant or Pure Variant Histology: Concordance Among 3 Commonly Used and Commercially Available AntibodiesHenning Reis, Rene Serrette, Jennifer Posada, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 1, 2017
DNA Damage Response and Repair Gene Alterations Are Associated with Improved Survival in Patients with Platinum-Treated Advanced Urothelial CarcinomaMin Yuen Teo, Richard M Bambury, Emily C Zabor, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 1, 2018
Alterations in DNA Damage Response and Repair Genes as Potential Marker of Clinical Benefit From PD-1/PD-L1 Blockade in Advanced Urothelial CancersMin Yuen Teo, Kenneth Seier, Irina Ostrovnaya, et al.
Bladder Cancer (Amsterdam, Netherlands)|January 24, 2022
<i>CD274</i> (<i>PD-L1</i>) Copy Number Changes (Gain) & Response to Immune Checkpoint Blockade Therapy in Carcinomas of the Urinary TractSounak Gupta, Chad M Vanderbilt, Yanming Zhang, et al.
European Urology|October 7, 2018
Genomic Differences Between "Primary" and "Secondary" Muscle-invasive Bladder Cancer as a Basis for Disparate Outcomes to Cisplatin-based Neoadjuvant ChemotherapyEugene J Pietzak, Emily C Zabor, Aditya Bagrodia, et al.
Nature Communications|December 21, 2017
Mutational patterns in chemotherapy resistant muscle-invasive bladder cancerDavid Liu, Philip Abbosh, Daniel Keliher, et al.
Pageof 5

Showing results (21-30 of 45) with videos related to

Sort By:
Pageof 5
Journal of the National Comprehensive Cancer Network : JNCCN|December 7, 2020
Prevalence of Insomnia in an Oncology Patient Population: An Irish Tertiary Referral Center ExperienceEmily C Harrold, Ahmad F Idris, Niamh M Keegan, et al.
European Urology|August 6, 2020
Fibroblast Growth Factor Receptor 3 Alteration Status is Associated with Differential Sensitivity to Platinum-based Chemotherapy in Locally Advanced and Metastatic Urothelial CarcinomaMin Yuen Teo, Jose Mauricio Mota, Karissa A Whiting, et al.
Cancers|June 10, 2023
Results from a Phase 1b/2 Study of Ibrutinib Combination Therapy in Advanced Urothelial CarcinomaNataliya Mar, Yousef Zakharia, Alejandro Falcon, et al.
British Journal of Cancer|January 21, 2021
Natural history, response to systemic therapy, and genomic landscape of plasmacytoid urothelial carcinomaMin Yuen Teo, Hikmat Al-Ahmadie, Kenneth Seier, et al.
The American Journal of Surgical Pathology|May 29, 2019
PD-L1 Expression in Urothelial Carcinoma With Predominant or Pure Variant Histology: Concordance Among 3 Commonly Used and Commercially Available AntibodiesHenning Reis, Rene Serrette, Jennifer Posada, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 1, 2017
DNA Damage Response and Repair Gene Alterations Are Associated with Improved Survival in Patients with Platinum-Treated Advanced Urothelial CarcinomaMin Yuen Teo, Richard M Bambury, Emily C Zabor, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 1, 2018
Alterations in DNA Damage Response and Repair Genes as Potential Marker of Clinical Benefit From PD-1/PD-L1 Blockade in Advanced Urothelial CancersMin Yuen Teo, Kenneth Seier, Irina Ostrovnaya, et al.
Bladder Cancer (Amsterdam, Netherlands)|January 24, 2022
<i>CD274</i> (<i>PD-L1</i>) Copy Number Changes (Gain) & Response to Immune Checkpoint Blockade Therapy in Carcinomas of the Urinary TractSounak Gupta, Chad M Vanderbilt, Yanming Zhang, et al.
European Urology|October 7, 2018
Genomic Differences Between "Primary" and "Secondary" Muscle-invasive Bladder Cancer as a Basis for Disparate Outcomes to Cisplatin-based Neoadjuvant ChemotherapyEugene J Pietzak, Emily C Zabor, Aditya Bagrodia, et al.
Nature Communications|December 21, 2017
Mutational patterns in chemotherapy resistant muscle-invasive bladder cancerDavid Liu, Philip Abbosh, Daniel Keliher, et al.
Pageof 5